ATE334200T1 - Chimäre rezeptoren - Google Patents
Chimäre rezeptorenInfo
- Publication number
- ATE334200T1 ATE334200T1 AT99919447T AT99919447T ATE334200T1 AT E334200 T1 ATE334200 T1 AT E334200T1 AT 99919447 T AT99919447 T AT 99919447T AT 99919447 T AT99919447 T AT 99919447T AT E334200 T1 ATE334200 T1 AT E334200T1
- Authority
- AT
- Austria
- Prior art keywords
- ligand
- domains
- cell
- chimeric receptors
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9809658.9A GB9809658D0 (en) | 1998-05-06 | 1998-05-06 | Biological products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334200T1 true ATE334200T1 (de) | 2006-08-15 |
Family
ID=10831530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99919447T ATE334200T1 (de) | 1998-05-06 | 1999-05-06 | Chimäre rezeptoren |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1075517B1 (de) |
| JP (1) | JP2002513569A (de) |
| AT (1) | ATE334200T1 (de) |
| AU (1) | AU768761B2 (de) |
| CA (1) | CA2328505A1 (de) |
| DE (1) | DE69932511T2 (de) |
| ES (1) | ES2268863T3 (de) |
| GB (1) | GB9809658D0 (de) |
| WO (1) | WO1999057268A1 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| EP1259601A2 (de) * | 2000-02-22 | 2002-11-27 | Ahuva Nissim | Chimäre und tcr phagen-display-bibliotheken, chimäre und tcr reagentien und anwendungsmethoden |
| EP1480514A4 (de) | 2002-03-01 | 2008-08-13 | Bristol Myers Squibb Co | Transgene nicht-menschliche säugetiere, die konstitutiv aktivierte tyrosinkinase-rezeptoren exprimieren |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US20090053210A1 (en) | 2006-09-01 | 2009-02-26 | Roland Buelow | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
| WO2013169691A1 (en) | 2012-05-07 | 2013-11-14 | Trustees Of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| EP2970985A1 (de) * | 2013-03-14 | 2016-01-20 | Fred Hutchinson Cancer Research Center | Zusammensetzungen und verfahren zur modifizierung von zellen für therapeutische ziele |
| WO2014145252A2 (en) | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| EP3087101B1 (de) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulierbarer chimärer antigenrezeptor |
| WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| BR112016018100A2 (pt) | 2014-02-07 | 2018-02-20 | Univ Mcmaster | acoplador antigênico de células t trifuncional, métodos e usos do mesmo |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| MX2017002205A (es) | 2014-08-19 | 2017-08-21 | Novartis Ag | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. |
| JP6839074B2 (ja) | 2014-09-17 | 2021-03-03 | ノバルティス アーゲー | 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング |
| KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
| RU2021118125A (ru) | 2014-12-29 | 2022-04-06 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| JP6961490B2 (ja) | 2015-04-08 | 2021-11-05 | ノバルティス アーゲー | Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法 |
| AU2016249005B2 (en) | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (de) | 2015-04-23 | 2018-02-28 | Novartis AG | Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| CA2992551A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| EP4643874A3 (de) | 2015-12-22 | 2026-02-11 | Novartis AG | Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-inhibitor zur kombinierten verwendung in der antikrebstherapie |
| EP3432924A1 (de) | 2016-03-23 | 2019-01-30 | Novartis AG | Zellsekretierte minikörper und verwendungen davon |
| US10188749B2 (en) | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019006781A2 (pt) | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| JP2020503883A (ja) | 2017-01-13 | 2020-02-06 | アジェナス インコーポレイテッド | Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法 |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CA3073055A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| CN111479925B (zh) | 2017-10-12 | 2024-03-08 | 麦克马斯特大学 | 具有y182t突变的t细胞-抗原偶联物及其方法和用途 |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| US12539308B2 (en) | 2018-01-08 | 2026-02-03 | The Trustees Of The University Of Pennsylvania | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
| KR20250099256A (ko) | 2018-01-18 | 2025-07-01 | 프레드 허친슨 캔서 센터 | 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경 |
| EP3749685A4 (de) | 2018-02-09 | 2021-12-22 | National University of Singapore | Aktivierung von chimären nkg2d-rezeptoren und verwendungen davon in der immuntherapie mit natürlichen killerzellen |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| TWI890660B (zh) | 2018-06-13 | 2025-07-21 | 瑞士商諾華公司 | Bcma 嵌合抗原受體及其用途 |
| US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
| US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
| EP3844186A4 (de) | 2018-08-29 | 2022-08-17 | National University of Singapore | Verfahren zur spezifischen stimulation des überlebens und der expansion von genetisch modifizierten immunzellen |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| EP3773918A4 (de) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | Cd19-gerichtete chimäre antigenrezeptoren und deren verwendungen in der immuntherapie |
| EP4065157A1 (de) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimäre cd19- und cd22-antigen-rezeptoren und verwendungen davon |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| AU2022283819A1 (en) | 2021-06-01 | 2024-01-04 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
| US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992010591A1 (en) * | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IE920716A1 (en) * | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| WO1993019163A1 (en) * | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
| KR100278352B1 (ko) * | 1993-07-16 | 2001-01-15 | 어니스트 엠. 해데드 | 수용체 키메라에 의한 세포 면역성의 전환 |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) * | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| GB9526131D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| GB9713473D0 (en) * | 1997-06-25 | 1997-09-03 | Celltech Therapeutics Ltd | Biological products |
-
1998
- 1998-05-06 GB GBGB9809658.9A patent/GB9809658D0/en not_active Ceased
-
1999
- 1999-05-06 CA CA002328505A patent/CA2328505A1/en not_active Abandoned
- 1999-05-06 JP JP2000547223A patent/JP2002513569A/ja active Pending
- 1999-05-06 DE DE69932511T patent/DE69932511T2/de not_active Expired - Lifetime
- 1999-05-06 EP EP99919447A patent/EP1075517B1/de not_active Expired - Lifetime
- 1999-05-06 ES ES99919447T patent/ES2268863T3/es not_active Expired - Lifetime
- 1999-05-06 AU AU37233/99A patent/AU768761B2/en not_active Ceased
- 1999-05-06 AT AT99919447T patent/ATE334200T1/de not_active IP Right Cessation
- 1999-05-06 WO PCT/GB1999/001417 patent/WO1999057268A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69932511D1 (de) | 2006-09-07 |
| AU3723399A (en) | 1999-11-23 |
| AU768761B2 (en) | 2004-01-08 |
| CA2328505A1 (en) | 1999-11-11 |
| GB9809658D0 (en) | 1998-07-01 |
| ES2268863T3 (es) | 2007-03-16 |
| EP1075517A1 (de) | 2001-02-14 |
| JP2002513569A (ja) | 2002-05-14 |
| EP1075517B1 (de) | 2006-07-26 |
| DE69932511T2 (de) | 2007-02-15 |
| WO1999057268A1 (en) | 1999-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69932511D1 (de) | Chimäre rezeptoren | |
| DE69938871D1 (de) | Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen | |
| SI0966454T1 (sl) | Disubstituirani biciklični heterocikli, njihova priprava in uporaba kot zdravila | |
| DE69633679D1 (de) | Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität | |
| PT911340E (pt) | Isoquinolinas-3-carboxamidas substituidas, sua preparacao e utilizacao como farmacos | |
| BRPI0507169A (pt) | polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos | |
| ES2130428T3 (es) | Cristales de insulina asp-b28. | |
| DE60115883D1 (de) | Infusion von flüssigkeiten in den menschlichen oder tierischen körper | |
| YU28897A (sh) | Biciklicno kondenzovani piridini | |
| BR9816155B1 (pt) | imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase, bem como medicamento e uso farmacêutico compreendendo as mesmas. | |
| ATE476495T1 (de) | Bazillus thuringiensis und dessen insektizide proteine | |
| ES2164914T3 (es) | Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar. | |
| BR0013012A (pt) | Composição contendo substância ativa, sua produção e seu uso | |
| CY1109221T1 (el) | Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum | |
| SI1276476T1 (sl) | Uporaba bradikardnih snovi pri zdravljenju miokardnih bolezni, povezanih s hipertrofijo, in nove kombinacije zdravil | |
| ES2080037T1 (es) | Medicamento de uso topico con actividad cicatrizante. | |
| DE60125232D1 (de) | Kleines säurelösliches sporenprotein und seine verwendungen | |
| CY1106363T1 (el) | Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων | |
| DE60232785D1 (de) | Tsg101-gag-wechselwirkung und ihre verwendung | |
| NO20004649L (no) | Modulatorer av funksjonen av reseptorer av TNF/NGF- reseptorfamilien og andre proteiner | |
| TR199801769T2 (xx) | D���k reg�lasyona diren�li C3 d�n��t�r�c�ler. | |
| IS2597B (is) | Lyf samsett úr R,R-formóteróli og siklesóníði | |
| ATE321768T1 (de) | Linker-nucleosid, seine herstellung und verwendung | |
| ATE165594T1 (de) | Triarylethylenderivate zur therapeutischen verwendung | |
| NZ514691A (en) | Method to type prion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |